Your browser doesn't support javascript.
loading
[Pathological features and immune microenvironment in HER-2 intratumoral heterogeneous breast cancers].
Yang, Y L; Song, Y M; Xue, H Q; Sun, H; Li, Y Q; Qian, X L; Jiao, J; Li, K P; Zhang, H; Guo, X J.
  • Yang YL; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Song YM; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Xue HQ; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Sun H; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Li YQ; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Qian XL; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Jiao J; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Li KP; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
  • Zhang H; Department of Oncology, Institute of Integrative Oncology, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China.
  • Guo XJ; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
Zhonghua Zhong Liu Za Zhi ; 45(2): 165-169, 2023 Feb 23.
Article en Zh | MEDLINE | ID: mdl-36781238
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma / Neoplasias de la Mama Triple Negativas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: Zh Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma / Neoplasias de la Mama Triple Negativas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: Zh Año: 2023 Tipo del documento: Article